These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7553236)

  • 1. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
    Bernsen MR; Dullens HF; Den Otter W; Heintz PM
    J Interferon Cytokine Res; 1995 Jul; 15(7):641-5. PubMed ID: 7553236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors.
    Mattijssen V; Balemans LT; Steerenberg PA; De Mulder PH
    Int J Cancer; 1992 Jul; 51(5):812-7. PubMed ID: 1612787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
    Wang L; Wu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):253-5. PubMed ID: 9387313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
    Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
    Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
    Katre NV
    J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
    Everse LA; Bernsen MR; Dullens HF; Den Otter W
    J Exp Ther Oncol; 1996 Jul; 1(4):231-6. PubMed ID: 9414409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
    Shanafelt AB; Lin Y; Shanafelt MC; Forte CP; Dubois-Stringfellow N; Carter C; Gibbons JA; Cheng SL; Delaria KA; Fleischer R; Greve JM; Gundel R; Harris K; Kelly R; Koh B; Li Y; Lantz L; Mak P; Neyer L; Plym MJ; Roczniak S; Serban D; Thrift J; Tsuchiyama L; Wetzel M; Wong M; Zolotorev A
    Nat Biotechnol; 2000 Nov; 18(11):1197-202. PubMed ID: 11062441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vivo antitumor activities of polyethylene glycol modified recombinant interleukin 2 (PEG-rIL-2) against murine hepatoma].
    Feng XS
    Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):256-8. PubMed ID: 8174461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12.
    Coughlin CM; Wysocka M; Trinchieri G; Lee WM
    Cancer Res; 1997 Jun; 57(12):2460-7. PubMed ID: 9192826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
    Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon.
    Bernsen MR; Van Barlingen HJ; Van der Velden AW; Dullens HF; Den Otter W; Heintz AP
    Int J Cancer; 1993 May; 54(3):513-7. PubMed ID: 8509227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective immunotherapy with local low doses of interleukin-2.
    Den Otter W; Maas RA; Koten JW; Dullens HF; Bernsen M; Klein WR; Rutten VP; Steerenberg PA; Balemans L; Ruitenberg EJ
    In Vivo; 1991; 5(6):561-5. PubMed ID: 1810439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels.
    Hiemstra C; Zhong Z; Van Tomme SR; van Steenbergen MJ; Jacobs JJ; Otter WD; Hennink WE; Feijen J
    J Control Release; 2007 Jun; 119(3):320-7. PubMed ID: 17475360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human interleukin-6.
    Inoue H; Kadoya T; Kabaya K; Tachibana K; Nishi N; Sato M; Ohsawa M; Mikayama T; Mori KJ
    J Lab Clin Med; 1994 Oct; 124(4):529-36. PubMed ID: 7930877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
    J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.